ENTYVIO 108 mg, solution for injection in a pre-filled syringe 2 syringes of 0.68 ml
Active ingredients: VÉDOLIZUMAB
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injection2 syringes of 0.68 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ENTYVIO 108 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 2 seringue(s) préremplie(s) en verre de 0,68 ml (conditionnement multiple)
- Marketing authorisation holder
- TAKEDA PHARMA (DANEMARK)
- Reimbursement according to BDPM
- 65 %
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- Rectocolite hémorragique (en 2ème ou 3ème ligne de traitement)<br>- Maladie de Crohn (en 3ème ligne de traitement) ; JOURNAL OFFICIEL ; 18/03/21
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 14 Jun 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69607230CIP73020866CIP133400930208663Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| VÉDOLIZUMABsolution | 108 mg · une seringue préremplie de 0,68 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.